Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies
- PMID: 20514213
- PMCID: PMC2811867
- DOI: 10.2174/157015909790031166
Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies
Abstract
Intravenous immunoglobulins (IVIg) have been shown in a number of trials, to be an effective treatment for the three main types of inflammatory neuropathies: Guillain-Barré Syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN). IVIg is thought to exert its immunomodulatory effects by affecting several components of the immune system including B-cells, T-cells, macrophages, complement, cytokines and cellular adhesion molecules. This article reviews the published evidence and the principal postulated mechanisms of action of intravenous immunoglobulins with special emphasis on inflammatory neuropathies.
Keywords: Chronic inflammatory demyelinating polyneuropathy; Guillain Barre syndrome; Intravenous immunoglobulins; inflammatory neuropathy; mechanisms of action; multifocal motor neuropathy..
Similar articles
-
Treatment of immune-mediated, dysimmune neuropathies.Acta Neurol Scand. 2005 Aug;112(2):115-25. doi: 10.1111/j.1600-0404.2005.00448.x. Acta Neurol Scand. 2005. PMID: 16008538 Review.
-
Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies.J Neuroimmunol. 2011 Feb;231(1-2):61-9. doi: 10.1016/j.jneuroim.2010.09.015. Epub 2010 Nov 5. J Neuroimmunol. 2011. PMID: 21056913 Review.
-
Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins.Biologics. 2010 Mar 24;4:45-9. doi: 10.2147/btt.s4881. Biologics. 2010. PMID: 20376173 Free PMC article.
-
Expression of chemokine receptors on peripheral blood mononuclear cells of patients with immune-mediated neuropathies treated with intravenous immunoglobulins.Eur J Neurol. 2006 Dec;13(12):1359-63. doi: 10.1111/j.1468-1331.2006.01521.x. Eur J Neurol. 2006. PMID: 17116220
-
Immune mediated neuropathies--an update on therapeutic strategies.J Neurol. 2004 Feb;251(2):127-37. doi: 10.1007/s00415-004-0323-5. J Neurol. 2004. PMID: 14991345 Review.
Cited by
-
Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations.Autoimmune Dis. 2014;2014:201657. doi: 10.1155/2014/201657. Epub 2014 Jan 14. Autoimmune Dis. 2014. PMID: 24527207 Free PMC article. Review.
-
The pathogenesis of multifocal motor neuropathy and an update on current management options.Ther Adv Neurol Disord. 2015 May;8(3):109-22. doi: 10.1177/1756285615575269. Ther Adv Neurol Disord. 2015. PMID: 25941538 Free PMC article. Review.
-
Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals.Drugs. 2022 Jun;82(8):865-887. doi: 10.1007/s40265-022-01726-y. Epub 2022 May 31. Drugs. 2022. PMID: 35639288 Free PMC article. Review.
-
Treatment strategies for autoimmune encephalitis.Ther Adv Neurol Disord. 2017 Aug 16;11:1756285617722347. doi: 10.1177/1756285617722347. eCollection 2018. Ther Adv Neurol Disord. 2017. PMID: 29399043 Free PMC article. Review.
-
Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.Nat Rev Neurol. 2014 Sep;10(9):493-506. doi: 10.1038/nrneurol.2014.141. Epub 2014 Aug 12. Nat Rev Neurol. 2014. PMID: 25112508 Free PMC article. Review.
References
-
- High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 1984;2:809–810. - PubMed
-
- Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Lancet. 1997;349:225–230. - PubMed
-
- Aukrust P, Froland SS, Liabakk NB, Muller F, Nordoy I, Haug C, Espevik T. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood. 1994;84:2136–2143. - PubMed
-
- Azulay JP, Blin O, Pouget J, Boucraut J, Bille-Turc F, Carles G, Serratrice G. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology. 1994;44:429–432. - PubMed
-
- Basta M, Illa I, Dalakas MC. Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barre syndrome, myasthenia gravis and dermatomyositis. J. Neuroimmunol. 1996;71:227–229. - PubMed
LinkOut - more resources
Full Text Sources